skip to main content

Secondary spontaneous pneumothorax in severe COPD — SCE Respiratory MCQ

Instant feedback + full explanation. One question, done properly.

HardGuidelinesSecondary spontaneous pneumothorax in severe COPDSCE Respiratory

A 74-year-old man with severe COPD (FEV1 28% predicted; TLCO 31% predicted) is admitted with his first spontaneous pneumothorax. The pneumothorax occupies approximately half of the left hemithorax and causes marked hypoxaemia, acute hypercapnia and haemodynamic compromise. He is treated with an intercostal drain and non-invasive ventilation. Five days later, the lung is fully re-expanded. The drain is patent and has shown no bubbling for 36 hours. A thoracic surgical multidisciplinary review concludes that severe frailty, pulmonary hypertension and right ventricular dysfunction confer prohibitive operative risk. He is concerned about another similarly severe event and, after discussion of procedural pain and uncertain success, prioritises a non-surgical intervention to reduce recurrence. Which management strategy best accords with current British Thoracic Society guidance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Perform chemical pleurodesis through the intercostal drain before its removal

Explanation lettering: C = shown as A · D = shown as B · E = shown as C · B = shown as D · A = shown as E

This is a secondary spontaneous pneumothorax because it has occurred in established severe COPD. Although it is his first episode, it produced profound physiological decompensation. BTS guidance specifically states that chemical pleurodesis may be considered to prevent recurrence of secondary spontaneous pneumothorax in patients with severe COPD who decompensated significantly, including during or after the first episode. His lung is re-expanded, the air leak has ceased, the drain remains available for intrapleural treatment, and surgery has been judged prohibitively hazardous. Chemical pleurodesis is therefore the best option, with appropriate peri-procedural analgesia. A avoids procedural morbidity but does not meet his stated priority of reducing recurrence after a life-threatening first secondary pneumothorax. B would provide definitive surgical recurrence prevention but conflicts with the multidisciplinary assessment that he cannot safely undergo surgery. C is a plausible non-surgical pleural intervention, but BTS positions autologous blood pleurodesis principally as treatment for an ongoing air leak when surgery is unsuitable; no leak remains. E has a similar role in selected non-surgical patients with persistent air leak and requires identification of a bronchial pathway feeding the leak. It is not a routine prophylactic intervention after the pneumothorax has sealed.

Reference: British Thoracic Society Guideline for pleural disease (11 July 2023) — https://www.brit-thoracic.org.uk/document-library/guidelines/pleural-disease/pleural-disease-full-supplement/